Shanghai Wibson Biotechnology: difference between revisions
Diff·revision 13 → 14·22:39, 4 Jun 2025
Difference between revision 13 and revision 14 of Shanghai Wibson Biotechnology. 2 lines changed; the page grew by 541 bytes.
| Revision 13 — 09:09, 22 May 2025 IncretinIvo (talk) add the standing talk-page note link to the banner 7,557 bytes ±0 | Revision 14 — 22:39, 4 Jun 2025 PrimarySrcPatia (talk) expand §Independent testing record 8,098 bytes +541 | ||
|---|---|---|---|
| 52 | Submitted reports on SWB material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties.{{r|reports}} | 52 | Submitted reports on SWB material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties.{{r|reports}} |
| 53 | 53 | ||
| + | 54 | Certificates described in the submitted set report [[Area percent purity|area percent]] purity; the [[Peptide content|peptide content]] and water determinations that convert a purity figure into a mass are issued on request against a named lot, and purchasers wanting them should ask at the point of order rather than after dispatch.{{r|usp1503}} As everywhere on this wiki, samples were purchaser-selected rather than [[Blind sampling|blind-drawn]], so the reports describe the vials tested and not the output they came from.{{r|reports}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |